Biogen plans to invest an additional $2 billion over the next three years to expand operations at its Research Triangle Park campuses in North Carolina. The expansion will enhance multiple modalities including antisense oligonucleotide manufacturing, clinical and commercial fill-finish capabilities, and advanced automation integration. This investment builds on Biogen’s prior $10 billion commitments in the region and supports pipeline advancement alongside strengthening North Carolina’s life sciences workforce.